Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab.

Firstly, we agree that uptake of biosimilar medications in Australia has been slower than expected owing to several factors, including those elucidated in the letter by Lim et al. Keywords: Pharmaceuticals; Medicolegal EN Pharmaceuticals Medicolegal 435 435 1 11/02/21 20211101 NES 211101 B I In reply: i b We thank Lim and colleagues1 for their insightful comments regarding the use biosimilar medicines in Australia; their letter highlights some pertinent issues. [Extracted from the article]